Rapid viral control in a world that needs it. ExeVir develops single-domain antibody-based therapies that help patients ward off viral infections. Our lead drug candidate is in accelerated development as a COVID-19 therapeutic.
Location: Belgium, East Flanders, Ghent
Total raised: $155.46M
Investors 4
| Date | Name | Website |
| - | Fund+ | fundplus.b... |
| - | UCB Ventur... | ucbventure... |
| - | V-Bio Vent... | v-bio.vent... |
| - | SFPIM | sfpim.be |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 28.06.2023 | Grant | $1.75M | - |
| 09.01.2023 | - | $26.71M | - |
| 24.05.2021 | Series A | $50M | - |
| 16.03.2021 | Series A | $50M | - |
| 28.07.2020 | Series A | $27M | - |
Mentions in press and media 22
| Date | Title | Description | Source |
| 28.06.2023 | ExeVir Bio Nets €1.6M Grant in Push to Pioneer Virus-Thwarti... | Key Takeaways: Belgium-based ExeVir Bio has raised €1.6 million in grant funding. The round was led ... | eustartup.... |
| 28.06.2023 | ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research | - | globenewsw... |
| 06.04.2023 | Nona Biosciences Enters into Collaboration Agreement with Ex... | CAMBRIDGE, Mass., April 6, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM H... | en.prnasia... |
| 06.04.2023 | Nona Biosciences Enters into Collaboration Agreement with Ex... | CAMBRIDGE, Mass., April 5, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM H... | einpresswi... |
| 13.03.2023 | ExeVir Bio and VIB Announce Data on a New Therapy for Preven... | Ghent, Belgium, 13 March 2023: ExeVir Bio, a biotech company developing robust single domain antibod... | fundplus.b... |
| 09.01.2023 | ExeVir Bio Secures EUR 25M Venture Debt Financing | ExeVir Bio, a Ghent, Belgium-based biotech company developing nanobody therapies for broad protectio... | finsmes.co... |
| 09.01.2023 | ExeVir Bio secures EUR 25 million venture debt financing fro... | - | globenewsw... |
| 09.01.2023 | Belgium’s ExeVir raises €25M from EIB to develop novel COVID... | Belgium-based ExeVir Bio, a clinical-stage biotechnology company developing nanobody-based therapeut... | siliconcan... |
| 20.10.2022 | ExeVir Bio Forges Ahead with Unique Next Generation COVID-19... | Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 varian... | fundplus.b... |
| 01.09.2021 | ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinic... | ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral ... | fundplus.b... |
Show more